(Alliance News) - Clinigen Group PLC has signed an exclusive agreement with Eyevance Pharmaceuticals to supply and distribute antifungal drug Natacyn, the company announced on Thursday.
The agreement will see marketing authorisations for Natacyn transferred to Clinigen or its appointed partners for commercial product supply in Argentina, Colombia, parts of Africa and five Asian territories including Hong Kong and Thailand. Clinigen will also provide physicians and pharmacists in a number of countries with access to the drug on an unlicensed basis.
Natacyn is an ocular antifungal drug for topical administration.
"We look forward to working with Eyevance to make Natacyn available to healthcare professionals," commented Chief Operating Officer & Head of Clinigen Products Division Sam Herbert.
"This agreement demonstrates the value of our lifecycle platform and our commitment in partnering with pharmaceutical companies to provide physicians and pharmacists around the world with access to important medicines that improve the quality of patients' lives."
In a separate announcement, Clinigen said the UK supply constraints on its Erwinase drug have been removed.
Previous restrictions on Erwinase, a treatment for acute lymphoblastic leukaemia, were introduced in April due to supply constraints.
Shares in Clinigen were trading down 0.7% at 610.50 pence on Thursday morning in London.
By Will Paige; willpaige@alliancenews.com
Copyright 2021 Alliance News Limited. All Rights Reserved.
